Monthly Archives: October 2017

Shifting Tide Favors Medication in Opioid Treatment

The nation’s opioid epidemic has reached fever pitch and is now being spotlighted by all levels of local and national media. This is obviously good news.

At the center of this discussion is what can be done to reduce opioid fatalities, and to provide addicted people a real opportunity to regain control over their lives. This discussion inevitably leads to examining the benefit of medication-assisted treatment.

Methadone, buprenorphine, and naloxone are the three leading alternatives for helping patients deal with the perpetual withdrawal sickness that comes from a physiological dependency on opioids.

In recent congressional testimony to members of Congress, Scott Gottlieb (Commissioner of the FDA) specifically heralded the life-saving benefits of methadone and similar medications.

His testimony included comments on the wealth of information behind the effectiveness of medication-assisted treatment. It is vitally important that legislative decision-makers obtain a clear understanding about what works and what does not in regard to coping successfully with this opioid crisis.

Time is of the essence because the present overdose fatality rate in the United States is over 64,000 per year. This number is beyond alarming. Here is an article that points to a possible positive shift in communities’ openness to having local opioid treatment nearby. Hopefully, this becomes a trend.